abt-737

ABT-737 is a BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w (EC50=30.3 nM/78.7 nM/197.8 nM). ABT-737 exhibits antitumor activity and anti-aging activity.

ABT-737-D8 is the deuterated form of ABT-737, a BH3 mimetic and potent inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with EC50 values of 30.3 nM, 78.7 nM, and 197.8 nM respectively. ABT-737 (T2099) disrupts the BCL-2/BAX complex and activates the intrinsic apoptotic pathway in a BAK-dependent and BIM-independent manner. Additionally, ABT-737 (T2099) induces autophagy and shows potential for research in acute myeloid leukemia (AML).

Opitor-0 is a highly selective OPA1 GTPase inhibitor with an IC₅₀ of 3 μM. Opitor-0 disrupts the stability of OPA1 oligomers, triggering mitochondrial cristae remodeling and fragmentation, which leads to massive release of cytochrome c and subsequently induces apoptosis. In anticancer studies, Opitor-0 has been shown to exhibit synergistic effects when combined with the Bcl-2 inhibitor ABT-737 or Venetoclax.

Meayamycin B ((+)-Meayamycin B) is a potent SF3B1 inhibitor that modulates pre-mRNA splicing to increase the expression of pro-apoptotic protein Mcl-1S and decrease Mcl-1L expression, without affecting the alternative splicing of Bcl-x. It synergizes with ABT-737 to induce apoptosis and demonstrates anticancer activity against non-small cell lung cancer.